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Abstract
Objective: Although the assessment of expression of serotonin-related genes in experimental
animals has become a common strategy to shed light on variations in brain serotonergic
function, it remains largely unknown to what extent the manipulation of serotonin levels causes
detectable changes in gene expression. We therefore chose to investigate how sub-acute depletion
or elevation of brain serotonin influences the expression of a number of serotonin-related genes
in six brain areas. Methods: Male Wistar rats were administered a serotonin synthesis inhibitor,
para-chlorophenylalanine (p-CPA), or a serotonin reuptake inhibitor, paroxetine, for 3 days
and then sacrificed. The expression of a number of serotonin-related genes in the raphe nuclei,
hypothalamus, amygdala, striatum, hippocampus and prefrontal cortex was investigated using
real-time quantitative PCR (rt-qPCR). Results:While most of the studied genes were uninfluenced
by paroxetine treatment, we could observe a robust downregulation of tryptophan hydroxylase-2
in the brain region where the serotonergic cell bodies reside, that is, the raphe nuclei. p-CPA
induced a significant increase in the expression of Htr1b and Htr2a in amygdala and of Htr2c
in the striatum and a marked reduction in the expression of Htr6 in prefrontal cortex; it also
enhanced the expression of the brain-derived neurotrophic factor (Bdnf) in raphe and hippocam-
pus. Conclusion:With some notable exceptions, the expression of most of the studied genes is left
unchanged by short-term modulation of extracellular levels of serotonin.
Significant outcomes
• Even drastic alterations of extracellular serotonin levels translate into comparatively
minor changes in serotonergic gene expression.
• While transcript levels of serotonergic genes in the raphe region and areas such as amyg-
dala and striatum were clearly affected by manipulations of serotonin levels; small or no
changes could be observed in the hypothalamus and prefrontal cortex.
• Short-term SSRI treatment is associated with downregulation of genes encoding enzymes
regulating serotonin synthesis in the raphe nuclei (Tph2, Ddc).
Limitations
• The dissection techniques employed unfortunately preclude analysis of potentially impor-
tant effects in sub-areas, such as differences in expression patterns between the dorsal and
median raphe nuclei.
• Although analysis of behavioural correlates of observed effects on gene expression could
have been potentially informing, this is not possible as no such tests were performed.
• As with all gene expression studies, the functional relevance (e.g. the impact on protein
levels and function) is somewhat unclear.
Introduction
The assumption that brain serotonin plays a key role in the regulation of various aspects of
human behaviour, and is the target for important psychoactive drugs, has inspired numerous
attempts tomeasure brain serotonergic activity in experimental animals. To this end, a variety of
techniques has been applied, among which assessment of the expression of serotonin-related
genes, not least because of its convenience, has become one of the most commonly used.
Thus, analysis of the expression of genes encoding serotonin-related proteins has, for example,
been applied for addressing how serotonergic transmission may be influenced by factors such as
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drugs (Barbon et al., 2011; Yamamura et al., 2011; McQuade et al.,
2004), electroconvulsive treatment (Shen et al., 2003), hormones
(McQueen et al., 1999; Donner & Handa, 2009), maternal separa-
tion (Gardner et al., 2009), stress (Bethea et al., 2013) and social
defeat (Boyarskikh et al., 2013).
While the underlying assumption for this strategy has been
that messenger RNA (mRNA) levels to some extent may reflect the
levels of the corresponding protein, and that regulation of gene
expression may be one important route for factors exerting long-
or short-term influences on brain serotonergic activity, it remains
to be clarified to what extent up- and downregulation of gene
expression are indeed important mechanisms for inducing
transient fluctuations and/or stable alterations in the status of a
certain transmitter, for example, for the purpose of maintaining
homeostasis. For example, while studies such as those cited above
indicate that the expression of serotonin-related genes is indeed
influenced by various external influences, it has been shown that
knockout of the gene encoding the serotonin-synthesising enzyme
tryptophan hydroxylase 2 (Tph2), leading to marked depletion of
brain serotonin levels, did not influence the expression of any of a
large number of serotonin-related genes that were assessed
(Kriegebaum et al., 2010). Thus, to facilitate the interpretation
of studies using mRNA assessment to reflect the status of brain
serotonergic transmission, it is important to increase the insight
into how responsive the expression of various serotonin-related
genes is to interventions known to influence extracellular serotonin
levels.
In this vein, the present study was undertaken to evaluate
the possible influence of short-term alterations in synaptic levels
of serotonin on a large number of serotonin-related genes, both
in the raphe nuclei, where the serotonergic cell bodies reside, and
in various terminal regions; the hypothesis being that such
changes would induce rapid adaptive responses in some but
not all of the studied genes. To this end, one group of animals
was injected for 3 days with the selective serotonin reuptake
inhibitor (SSRI) paroxetine, that is, a drug that is likely to cause
at least a moderate increase in extrasynaptic levels of serotonin in
at least some of the studied terminal regions (see refs in Fuller,
1994) and, at the same time, to dampen the electrical activity of
the serotonergic cell bodies in the raphe region (as the result of
an autoreceptor-mediated feedback) (Hajós et al., 1995).
Another group of rats was subjected to 3 days of treatment
with the serotonin synthesis inhibitor, para-chlorophenylalanine
(p-CPA), in a regimen known to cause a depletion of tissue sero-
tonin exceeding 95% (Miczek et al., 1975; Näslund et al., 2013).
Supporting that the applied treatments do in fact produce a sig-
nificant alteration of serotonergic output, they are known to
elicit reciprocal behavioural effects that are likely to be the result
of such an influence; thus, while p-CPA enhances aggression
(Miczek et al., 1975) and sexual activity (Tagliamonte et al.,
1969) and reduces anxiety-like behaviour (as assessed, e.g.
using the elevated plus maze; Treit et al., 1993; Näslund et al.,
2015), acute administration of SSRIs leads to the opposite
effects (Griebel et al., 1994; Vega Matuszcyk et al., 1998;
Ho et al., 2001).
Aims of the study
We aimed to investigate, by way of measurement of transcript lev-
els of a comprehensive set of serotonergic genes, the responsiveness
of the serotonin system to short-term manipulation of synaptic
serotonin levels. We also desired to characterise the effects of such
interventions per se and to compare these results with earlier work
by other groups.
Experimental procedures
Study design and protocol
Thirty-three male Wistar rats, aged 9–10 weeks at arrival,
were kept in an animal facility for 5 weeks, whereupon they
were randomly divided into three equal groups and administered
paroxetine, p-CPA or saline for 3 days. On the morning of the 4th
day, they were given a final injection and sacrificed 2 h later. Brains
were immediately extracted and dissected on dry ice.
In five regions receiving substantial serotonergic innervation,
that is, amygdala, hippocampus, striatum, hypothalamus and
prefrontal cortex, we assessed the genes encoding i) nine different
serotonergic receptor subtypes, 5HT1A (Htr1a), 5HT1B (Htr1b),
5-HT1D (Htr1d), 5-HT2A (Htr2a), 5-HT2C (Htr2c), 5-HT3A
(Htr3a), 5-HT4 (Htr4), 5-HT6 (Htr6) and 5-HT7 (Htr7); ii) the
two subtypes of the monoamine metabolising enzyme, monoamine
oxidases A and B (Maoa andMaob); iii) brain-derived neurotrophic
factor (Bdnf), which is a protein known to exert an important impact
on serotonergic transmission (Rumajogee et al., 2005); iv) the BDNF
receptor (Ntrk1); and v) P11 (S100a10), which is another protein
attributed to important interactions with brain serotonergic neurons
(Anisman et al., 2008; gene names within parentheses). In the raphe
nuclei, where the serotonergic cell bodies reside, we studied a num-
ber of genes known to be expressed by serotonergic neurons and/or
suggested to interact with these, such as those encoding i) the three
serotonergic autoreceptors, that is, Htr1a, Htr1b and Htr1d; ii)
the enzymes involved in the synthesis of serotonin, that is, one of the
two isoforms of tryptophan hydroxylase (Tph2) and amino acid-
decarboxylase (Ddc); iii) the serotonin transporter (Slc6a4); iv) the
monoamine vesicular transporter (Slc18a2); v) Maoa and Maob;
vi) three transcription factors expressed by serotonergic neurons
and of importance for the development (and possibly maintenance)
of serotonergic neurons and expressed by these: GATA-2 (Gata2;
Craven et al., 2004), MASH-1 (Ascl1; Pattyn et al., 2004) and
PET-1 (Fev) (Liu et al., 2010); vii) Bdnf; viii) Ntrk2; and ix)
S100a10. Finally, in order to shed further light on the possible
differences between different regions with respect to how strongly
they were influenced by the two interventions, the expression of
the immediate-early gene c-Fos was assessed both in raphe and in
the different terminal regions.
Animals
Animals were obtained from Taconic (Ejby, Denmark) and housed
with a 12-h light/dark cycle (lights on at 06:00 a.m.) and with
standard chow and water available ad libitum. All procedures were
carried out in accordance with national and European legislation
and with the approval of the local ethics committee and in accor-
dance with the institutional guidelines.
Drug treatment
The p-CPA (Sigma-Aldrich, St Louis, MO, USA) was dissolved in
0.9% saline and administered intraperitoneally as one injection of
300 mg/kg per day for 3 days, with the last injection being given
roughly 24 h before sacrifice. Paroxetine hydrochloride (Jai
Radhe Chemicals, Ahmedabad, India) was dissolved in 0.9% saline
and administered subcutaneously at a dose of 10 mg/kg 2 times per
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day. All animals were given two injections daily 10–12 h apart; the
paroxetine group was given paroxetine 10 mg/kg at both occasions,
the p-CPA group was given p-CPA (300 mg/kg) in the first injec-
tion and saline in the next and the saline group was given saline
at both occasions. On the 4th day, the paroxetine group was
administered a last dose of paroxetine 2 h before sacrifice, while
the other two groups received saline.
Dissection
Brains were extracted immediately after decapitation. The extended
amygdala, hippocampus, striatum, hypothalamus, prefrontal cortex
and raphe nuclei were dissected out for gene expression analysis.
Brain tissue samples were immediately frozen on dry ice and
stored at −80°C.
Gene expression
Individual samples of brain tissue were homogenised in Qiazol
(Qiagen, Hilden, Germany) using a TissueLyzer (Qiagen). Total
RNA was extracted with an RNeasy Lipid Tissue Mini Kit
(Qiagen) using a QiaCube (Qiagen). RNA quantities were deter-
mined, and quality assessed, by means of spectrophotometric
measurements (Nanodrop 1000; Thermo Scientific, Wilmington,
DE, USA). For complementary DNA (cDNA) synthesis, 4000 ng
of total RNA was reversely transcribed using random hexamers
(Applied Biosystems, Sundbyberg, Sweden) and Superscript III
reverse transcriptase (Invitrogen Life Technologies, Paisley,
UK) according to the manufacturer’s description. Recombinant
RNaseout® Ribonuclease Inhibitor (Invitrogen) was added to prevent
RNase-mediated degradation. All cDNA reactionswere run in dupli-
cate and the products pooled for further analysis.
Real-time qPCR was performed by means of TaqMan® Custom
Arrays using TaqMan probe and primer sets for target genes
and reference genes chosen from an online catalogue (Applied
Biosystems). Two separate cards were used: one to investigate
the raphe region and one to investigate the various target areas.
Names and assay numbers for genes investigated are shown in
Supplementary Table 1. The sets were factory loaded into the
384 wells of the TaqMan® Array, each port being loaded with
cDNA corresponding to 500 ng total RNA combined with
nuclease-free water and 50 μl TaqMan® Gene Expression Master
Mix (Applied Biosystems) to a final volume of 100 μl. The
TaqMan® Arrays were analysed using the 7900 HT system with
a TaqMan Array Upgrade (Applied Biosystems). Thermal cycling
conditions were 50°C for 2 min and 94.5°C for 10 min, followed by
40 cycles of 97°C for 30 s and 59.7°C for 1 min.
All reactions were run in duplicate, and reactions were excluded
if the Cycle threshold (CT) values of the duplicates differed by
more than 5%. By means of the NormFinder algorithm (http://
moma.dk/normfinder-software), a combination of Hmbs and
Ppia was found to display the highest stability among the four
reference genes in all areas examined and was therefore used to nor-
malise the expression levels. Gene expression values were calculated
based on theΔΔCt method (Livak & Schmittgen, 2001). Table 1 pro-
vides the relative expression of each gene;ΔΔCt values for each gene
are given in Supplementary Table 2.
Statistical analyses
Student’s t-testswere used to test for treatment effects as compared to
placebo; we chose not to use an analysis of variance-based approach
as we did not aim to investigate the possible differences between
SSRI- and p-CPA-treated animals. As this was a hypothesis-driven
study, where some of the observed genes were expected to change
in a certain direction, whereas for others there was no a priori
hypothesis, the results are presented without any correction for
multiple testing; nevertheless, permutation analyses were performed
and are included in the supplementary online information
(Supplementary Table 3). SPSS for Mac version 21 (IBM, Chicago,
IL, USA) was used for all statistical procedures, except for the




Htr1b, Htr2a and Htr3a were upregulated in the amygdala, while
Htr2cwas upregulated in the striatum.Htr4 was upregulated in the
amygdala, while Htr6 was downregulated in hippocampus and
prefrontal cortex.Maobwas upregulated in the striatum and raphe.
Bdnf was upregulated in the amygdala, hippocampus and raphe,
while Ntrk2 was upregulated in the striatum. Slc6a4 was downre-
gulated in the hypothalamus, prefrontal cortex and raphe. S100a10
was upregulated in the hippocampus. Ddc was downregulated in
the raphe. Fos was upregulated in the hippocampus and raphe
(Table 1). Nine of the observed effects survived correction for
multiple comparisons by means of permutation analyses with
subsequent area-by-area Holm-Bonferroni correction: Htr1b and
Htr2a in the amygdala; Bdnf in the hippocampus; Htr2c in the
striatum; Htr4 and Slc6a4 in the prefrontal cortex; and Bdnf,
Slc6a4 and Ddc in the raphe (Supplementary Table 3).
Paroxetine
Htr1a andHtr1d were upregulated in the hippocampus.Htr2a was
downregulated in the hypothalamus. Htr2c and Htr3a were upre-
gulated in the striatum, and the latter gene was also upregulated in
the amygdala. Htr4 was upregulated in the amygdala. Maoa was
upregulated in the amygdala, while Maob was upregulated in
amygdala and hippocampus. Ntrk2 and Slc6a4 were upregulated
in the striatum. Three genes were significantly downregulated
by paroxetine in the raphe region: Tph2, Ddc and Fev. Fos was
upregulated in hypothalamus (Table 1). None of the effects except
for the downregulation ofTph2 in the raphe survived correction for
multiple comparisons (Supplementary Table 3).
Discussion
One major conclusion of this study is that both paroxetine and
p-CPA left the expression of most of the studied genes unaffected,
the major exceptions being discussed below. It may hence be con-
cluded either that short-term changes in extracellular serotonin
levels and/or serotonergic cell firing, elicit an adaptive modula-
tion of the formation of only a minority of the proteins in ques-
tion, or that such adaptations are not easily captured using
conventional assessment of mRNA expression. Of note is, for
example, that the expression of the gene encoding the 5HT1A
receptor (Popova & Naumenko, 2013), which is regarded as
one of the most important mediators of the effects of serotonin
on postsynaptic neurons, and which also serves as an autorecep-
tor at serotonergic cell bodies, was not influenced by any of the
two treatments.
The observation that serotonin depletion induced a marked
upregulation of Bdnf both in the raphe region and in the
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Table 1. Gene expression effects of short-term manipulation of synaptic 5-HT levels
Amygdala Hippocampus Striatum Hypothalamus Prefrontal cortex Raphe
p-CPA SSRI p-CPA SSRI p-CPA SSRI p-CPA SSRI p-CPA SSRI p-CPA SSRI
Htr1a 1.03 1.11 1.06 1.12* 0.83 0.83 0.99 0.96 1.05 1.18 0.89 (p= 0.01) 0.92
Htr1b 1.20*** 1.05 1.01 0.89 1.20 (p= 0.05) 1.11 1.09 0.91 1.09 1.09 0.69 0.99
Htr1d 1.17 1.00 1.09 1.59* 1.18 (p= 0.08) 1.16 (p= 0.07) 0.90 1.06 0.88 1.25 0.89 0.89
Htr2a 1.18** 0.96 1.15 0.98 1.22 (p= 0.05) 0.87 1.05 0.81** 0.99 0.95
Htr2c 0.91 1.10 1.06 0.94 1.53** 1.43** 0.93 0.98 1.00 0.86
Htr3a 1.18* 1.15* 1.11 0.99 1.21 (p= 0.09) 1.26* 1.10 0.92 0.95 1.02
Htr4 1.12* 1.20** 1.14 1.20 1.09 1.10 0.93 (p= 0.09) 0.99 1.05 1.09
Htr6 1.00 1.03 0.84* 1.03 1.01 1.07 0.97 1.04 0.71*** 0.92
Htr7 1.08 1.10 (p= 0.09) 1.08 1.10 0.97 0.99 0.99 0.98 1.00 0.93
Maoa 0.96 1.13* 0.96 1.12 (p= 0.7) 1.02 1.11 (p= 0.09) 0.92 (p= .08) 0.96 0.90 0.99 0.90 (p= 0.09) 1.04
Maob 1.13 (p= 0.1) 1.23** 1.13 1.14** 1.19* 1.18 (p= 0.05) 1.14 0.98 0.99 1.18 1.13* 0.96
Bdnf 1.23* 0.87 (p= 0.07) 1.46*** 1.03 1.05 0.79 1.13 0.88 1.04 0.79 1.77** 0.85
Ntrk2 1.08 1.04 1.11 1.00 1.13* 1.07* 1.01 1.00 0.92 1.07 0.95 0.94
S100a10 1.11 1.13 1.08* 1.09 (p= 0.1) 0.79 0.84 1.06 0.94 1.12 0.84 0.97 0.98
Slc6a4 0.90 1.08 0.90 1.27 0.72 (p= 0.06) 1.35* 0.51* 0.76 0.65* 1.25 0.65* 0.71 (p= 0.08)
Tph2 0.82 0.56**
Ddc 0.80* 0.78*
Slc18a2 0.93 0.84 (p= 0.1)
Fev 0.76 (p= 0.07) 0.66*
Gata2 0.84 0.91
Ascl1 0.87 (p= 0.07) 1.10
Fos 1.12 1.23 1.57*** 1.23 1.06 1.53 (p= 0.07) 1.26 (p= 0.1) 1.33* 0.80 1.36 1.45*** 1.13
Treatment effects of short-term treatment with p-CPA or paroxetine. Numbers indicate expression levels relative to the saline group, with asterisks (*) indicating level of significance for the comparison.
n= 10–11 (Slc6a4 in amygdala= 9)
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hippocampus is in agreement with an earlier study (Zetterström
et al., 1999) as well as with a report on Tph2 knock-out mice
(Migliarini et al., 2012). The lack of effect of short-term adminis-
tration of paroxetine on Bdnf, both in raphe and in the terminal
regions, is also in agreement with the literature, where acute and
sub-acute SSRI treatment has been reported to exert either modest
down-regulating or no effects on the expression of this gene
(Nibuya et al., 1995; Zetterström et al., 1999; Mannari et al.,
2008). Long-term administration of SSRIs, on the other hand, is
reported to increase Bdnf expression (Mannari et al., 2008), that
is, to exert an effect similar to that of acute serotonin depletion.
Apart from the effect on Bdnf, there were very minor effects of
72 h of serotonin depletion on the expression of serotonin-related
genes in the raphe. This finding is indirectly in line with previous
reports according to which p-CPA does not influence the firing rate
of raphe serotonergic neurons, that is, that these neurons are not
under tonic feedback inhibition by extracellular levels of serotonin
(Aghajanian et al., 1970; Chaput et al., 1990). Likewise, blockade of
5-HT1A autoreceptors does not exert any effect on raphe firing
when administered per se (Mundey et al., 1994).
According to the traditional concept of denervation supersen-
sitivity, an expected effect of serotonin depletion on serotonergic
receptors would be one of compensatory upregulation. In line with
this, we observed an increase inHtr1b andHtr2a expression in the
amygdala and of Htr2c in the striatum, in p-CPA-treated animals,
the latter finding being in line with a previous study (Compan et al.,
1998). In contrast, none of the other receptors were significantly
upregulated by this treatment. While it cannot be excluded that
also other receptors would have been upregulated had the
depletion lasted for longer than 72 h, our results suggest that
5-HT1B and 5-HT2A receptors in the amygdala, and 5-HT2C
receptors in the striatum, are particularly sensitive to changes in
extracellular levels of serotonin.
With respect to the 5-HT6 receptor, the opposite effect of sero-
tonin depletion was found; p-CPA thus induced a marked reduc-
tion in the expression of the gene encoding this receptor in
prefrontal cortex and a somewhat less pronounced effect in the
same direction in the hippocampus. A previous study found
support for 5-HT6 receptors in the prefrontal cortex to exert an
inhibitory influence on the local release of serotonin (Schechter
et al., 2008); so from the perspective of adaptive feedback,
a drug-induced shortage of serotonin leading to a downregulation
of a receptor inhibiting serotonin release bears some logic.
Previous studies have suggested that serotonin depletion, as
obtained using reserpine for 3 days (Xiao et al., 1999) or p-CPA
for 1–2 (Rattray et al., 1996) or 10 days (Linnet et al., 1995), leads
to downregulation of the expression of the gene encoding the sero-
tonin transporter, that is, to a change in the expression of
this gene, which would make sense from an adaptive point of view.
Our observation of reduced levels of Slc6a4 expression in several
brain regions of serotonin-depleted animals is hence in line with
earlier work.
It has since long been known that inhibition of serotonin
reuptake, as the result of an autoreceptor-mediated feedback, elic-
its an immediate reduction in serotonergic cell firing (Gallager &
Aghajanian, 1975; Hajós et al., 1995) as well as a decrease in sero-
tonin turnover (Carlsson et al., 1969; Fuller &Wong, 1977). In line
with these observations, raphe Tph2 expression was markedly
reduced in rats exposed to paroxetine for 3 days. The TPH2
enzyme being downregulated by SSRIs has been shown before,
both by means of histochemical methods (MacGillivray et al.,
2010) and by means of assessment of mRNA expression
(Dygalo et al., 2006; Abumaria et al., 2007; Shishkina et al.,
2007; Klomp et al., 2014); however, a common view has been that
such an effect requires weeks of treatment to be at hand (Dygalo
et al., 2006). In contrast, our results suggest that increased extrac-
ellular serotonin levels in the raphe region leads to a downregula-
tion of Tph2 that takes no more than 3 days to be manifest.
In addition, it is of note that two other raphe genes that are (more
or less) exclusively expressed by serotonergic neurons, and the
expression of which hence might be expected to be influenced
by the activity of the neurons, that is, Ddc and Fev, also displayed
reduced expression in SSRI-treated animals, and that there was a
tendency for Slc6a4 in the same direction. A previous study showed
reduced expression of Slc6a4 after 7, but not 4, days of fluoxetine
treatment (Neumaier et al., 1996). With respect to the influence
of paroxetine on serotonergic receptors, it is noteworthy that this
was always one of up- rather than downregulation, with Htr2a in
the hypothalamus being the sole exception.
It is noteworthy that the striatum, the hippocampus and the
amygdala were the areas that appeared most influenced by sub-
acute SSRI treatment and that this observation is also supported
by the assessment of c-Fos activation (Beck, 1995; Torres et al.,
1998; Morelli et al., 1999). Partly in line with this, previous studies
using in vivo microdialysis have shown short-term administration
of an SSRI to cause a marked increase in the extracellular levels of
serotonin in the striatum (Kalén et al., 1989), hippocampus (Sabol
et al., 1992; Bosker et al., 1995) and the amygdala (Sundblad &
Eriksson, 1997; Bosker et al., 2001); in contrast, the possible effect
of the same treatment in prefrontal cortex, where we observed no
effects on gene expression, appears less clear-cut and has remained
a matter of controversy (Sarkissian et al., 1990; Adell & Artigas,
1991; Gartside et al., 1995).
To summarise, in order to facilitate the interpretation of
studies assessing the expression of serotonin-related genes to gain
insight into the status of brain serotonergic neurotransmission after
various experimental interventions, we have explored to what extent
gene expression is influenced by short-term changes in extracellular
levels of serotonin and/or in serotonergic nerve activity. The results
show some of the studied genes to bemarkedly influencedwhilemost
were not. Follow-up studies assessing the possible influence of similar
manipulations of the extracellular levels of serotonin being in place
for a more prolonged time period are warranted.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/neu.2020.9.
Acknowledgements. The authors gratefully acknowledge the expert
technical assistance of Ms. Gunilla Bourghardt, Ms. Inger Oscarsson and Ms.
Ann-Christine Reinhold. We thank the Genomics Core Facility at Sahlgrenska
Academy, University of Gothenburg, Sweden, for participating in the gene expres-
sion experiments.
Authors’ contributions. JN and EE designed the study. JN and ES performed
the experiments. SN provided statistical expertise. JN wrote the first draft of the
manuscript. All authors contributed to, and have approved, the final version of
the manuscript.
Financial support. Financial support was obtained from the Swedish
Science Council (grant number K2010-61x-4961-01-3), Söderberg’s Foundation
(MT30/09), Hållsten’s Foundation (N/A) and the Brain Foundation
(FO2011-0293). Apart from providing grants, none of the funding sources
took any active part in this work.
Conflicts of interest. None of the authors report any conflict of interest of
relevance to the work here presented.
Acta Neuropsychiatrica 163
https://www.cambridge.org/core/terms. https://doi.org/10.1017/neu.2020.9
Downloaded from https://www.cambridge.org/core. Chalmers Tekniska Högskola, on 03 Dec 2020 at 13:35:04, subject to the Cambridge Core terms of use, available at
References
Abumaria N, Rygula R, Hiemke C, Fuchs E, Havemann-Reinecke U, Rüther
E and Flügge G (2007) Effects of chronic citalopram on serotonin-related
genes and stress-regulated genes in the dorsal raphe nucleus of the rat.
European Neuropsychopharmacology 17(6–7), 417–429.
Adell A and Artigas F (1991) Differential effects of clomipramine given
locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei
and frontal cortex. An in vivo brainmicrodialysis study.Naunyn Schmiedebergs
Archives of Pharmacology 343(3), 237–244.
Aghajanian GK, Graham AW and Sheard MH (1970) Serotonin-containing
neurons in brain: depression of firing by monoamine oxidase inhibitors.
Science 169(3950), 1100–1102.
Anisman H, Du L, Palkovits M, Faludi G, Kovacs GG, Szontagh-Kishazi P,
Merali Z and Poulter MO (2008) Serotonin receptor subtype and p11
mRNA expression in stress-relevant brain regions of suicide and control
subjects. Journal of Psychiatry & Neuroscience 33(2), 131–141.
BarbonA, Orlandi C, La Via L, Caracciolo L, TarditoD,Musazzi L,Mallei A,
Gennarelli M, Racagni G, Popoli M and Barlati S (2011). Antidepressant
treatments change 5-HT2C receptor mRNA expression in rat prefrontal/
frontal cortex and hippocampus. Neuropsychobiology 63(3), 160–168.
Beck CH (1995). Acute treatment with antidepressant drugs selectively
increases the expression of c-fos in the rat brain. Journal of Psychiatry &
Neuroscience 20(1), 25–32.
Bethea CL, Phu K, ReddyAP and Cameron JL (2013). The effect of short-term
stress on serotonin gene expression in high and low resilient macaques.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 44(5),
143–153.
Bosker FJ, Klompmakers AA andWestenbergHG (1995). Effects of single and
repeated oral administration of fluvoxamine on extracellular serotonin in the
median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology
34(5), 501–508
Bosker FJ, Cremers TI, Jongsma ME, Westerink BHC, Wikström HV and
den Boer JA (2001). Acute and chronic effects of citalopram on postsynaptic
5-hydroxytryptamine1A receptor-mediated feedback: a microdialysis study
in the amygdala. Journal of Neurochemistry 76(6), 1645–1653.
Boyarskikh UA, Bondar NP, Filipenko ML and Kudryavtseva NN (2013).
Downregulation of serotonergic gene expression in the raphe nuclei of the
midbrain under chronic social defeat stress in male mice. Molecular
Neurobiology 48(1), 13–21.
Carlsson A, Jonason J and Lindquist M (1969). On the mechanism of
5-hydroxytryptamine release by thymoleptics. Journal of Pharmacy and
Pharmacology 21(11), 769–773.
Chaput Y, Lesieur P and de Montigny C (1990). Effects of short-term
serotonin depletion on the efficacy of serotonin neurotransmission:
electrophysiological studies in the rat central nervous system. Synapse
6(4), 328–337.
Compan V, Segu L, Buhot MC and Daszuta A (1998). Selective increases
in serotonin 5-HT(1B/1D) and 5-HT(2A/2C) binding sites in adult rat basal
ganglia following lesions of serotonergic neurons. Brain Research 793(1–2),
103–111.
Craven SE, Lim KC, Ye W, Engel JD, de Sauvage F and Rosenthal A (2004).
Gata2 specifies serotonergic neurons downstream of sonic hedgehog.
Development 131(5), 1165–1173.
Donner N and Handa RJ (2009). Estrogen receptor beta regulates the expres-
sion of tryptophan-hydroxylase 2 mRNAwithin serotonergic neurons of the
rat dorsal raphe nuclei. Neuroscience 163(2), 705–718.
Dygalo NN, Shishkina GT, Kalinina TS, Yudina AM and Ovchinnikova ES
(2006). Effect of repeated treatment with fluoxetine on tryptophan
hydroxylase-2 gene expression in the rat brainstem. Pharmacology, Biochemistry
and Behavior 85(1), 220–227.
Fuller RW andWong DT (1977). Inhibition of serotonin reuptake. Federation
Proceedings 36(8), 2154–2158.
Fuller RW (1994). Uptake inhibitors increase extracellular serotonin concen-
tration measured by brain microdialysis. Life Sciences 55(3), 163–167.
Gallager DW and Aghajanian GK (1975). Effects of chlorimipramine
and lysergic acid diethylamide on efflux of precursor-formed 3-H-serotonin:
correlations with serotonergic impulse flow. Journal of Pharmacology and
Experimental Therapeutics 193(3), 785–795.
Gardner KL, Hale MW, Lightman SL, Plotsky PM and Lowry CA (2009).
Adverse early life experience and social stress during adulthood interact
to increase serotonin transporter mRNA expression. Brain Research
1305(1–2), 47–63.
Gartside SE, Umbers V, Hajós M and Sharp T (1995). Interaction between a
selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT
cell firing and extracellular 5-HT. British Journal of Pharmacology 115(6),
1064–1070.
Griebel G, Moreau J-L, Jenck F, Misslin R and Martin JR (1994). Acute and
chronic treatment with 5-HT reuptake inhibitors differentially modulate
emotional responses in anxiety models in rodents. Psychopharmacology
113(3–4), 463–470.
Hajós M, Gartside SE and Sharp T (1995). Inhibition of median and dorsal
raphe neurones following administration of the selective serotonin reuptake
inhibitor paroxetine. Naunyn Schmiedebergs Archives of Pharmacology
351(6), 624–629.
HoHP, OlssonM,Westberg L, Melke J and Eriksson E (2001). The serotonin
reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female
rats: an animal model of premenstrual irritability? Neuropsychopharmacology
24(5), 502–510.
Kalén P, Strecker RE, Rosengren E and Björklund A (1989). Regulation of
striatal serotonin release by the lateral habenula-dorsal raphe pathway in
the rat as demonstrated by in vivo microdialysis: role of excitatory amino
acids and GABA. Brain Research 492(1–2), 187–202.
Klomp A, Hamelink R, Feenstra M, Denys D and Reneman L (2014).
Increased response to a 5-HT challenge after discontinuation of chronic sero-
tonin uptake inhibition in the adult and adolescent rat brain. PLoS One 9(6),
e99873.
Kriegebaum C, Song N-N, Gutknecht L, Huang Y, Schmitt A, Reif A, Ding
YQ and Lesch KP (2010). Brain-specific conditional and time-specific
inducible Tph2 knockout mice possess normal serotonergic gene expression
in the absence of serotonin during adult life. Neurochemistry International
57(5), 512–517.
Linnet K, Koed K, Wiborg O and Gregersen N (1995). Serotonin depletion
decreases serotonin transporter mRNA levels in rat brain. Brain Research
697(1–2), 251–253.
Liu C, Maejima T,Wyler SC, Casadesus G, Herlitze S and Deneris ES (2010).
Pet-1 is required across different stages of life to regulate serotonergic
function. Nature Neuroscience 13(10), 1190–1198.
Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2-[Delta][Delta] CT method.
Methods 25(4), 402–408.
MacGillivray L, Lagrou LM, Reynolds KB, Rosebush PI and Mazurek MF
(2010). Role of serotonin transporter inhibition in the regulation of trypto-
phan hydroxylase in the brainstem raphe nuclei: time course and regional
specificity. Neuroscience 171(2), 407–420.
Mannari C, Origlia N, Scatena A, del Debbio A, Catena M, dell’Agnello G,
Barraco A, Giovannini L, Dell’osso L, Domenici L and Piccinni A (2008).
BDNF level in the rat prefrontal cortex increases following chronic but
not acute treatment with Duloxetine, a dual acting inhibitor of noradrenaline
and serotonin re-uptake. Cellular and Molecular Neurobiology 28(3),
457–468.
McQuade R, LeitchMM,Gartside SE and Young AH (2004). Effect of chronic
lithium treatment on glucocorticoid and 5-HT1A receptor messenger RNA
in hippocampal and dorsal raphe nucleus regions of the rat brain. Journal of
Psychopharmacology 18(4), 496–501.
McQueen JK,WilsonH, Sumner BE and FinkG (1999). Serotonin transporter
(SERT) mRNA and binding site densities in male rat brain affected by sex
steroids. Molecular Brain Research 63(2), 241–247.
Miczek KA, Altman JL, Appel JB and Boggan WO (1975). Para-
chlorophenylalanine, serotonin and killing behavior. Pharmacology,
Biochemistry and Behavior 3(3), 355–361.
Migliarini S, Pacini G, Pelosi B, Lunardi G and Pasqualetti M (2012). Lack of
brain serotonin affects postnatal development and serotonergic neuronal
circuitry formation. Molecular Psychiatry 18(10), 1106–1118.
164 Näslund et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/neu.2020.9
Downloaded from https://www.cambridge.org/core. Chalmers Tekniska Högskola, on 03 Dec 2020 at 13:35:04, subject to the Cambridge Core terms of use, available at
Morelli M, Pinna A, Ruiu S and del Zompo M (1999). Induction of
Fos-like-immunoreactivity in the central extended amygdala by antidepressant
drugs. Synapse 31(1), 1–4.
Mundey MK, Fletcher A and Marsden CA (1994). Effect of the putative
5-HT1A antagonists WAY100135 and SDZ 216-525 on 5-HT neuronal
firing in the guinea-pig dorsal raphe nucleus. Neuropharmacology 33(1),
61–66.
Näslund J, Studer E, Nilsson K,Westberg L and Eriksson E (2013). Serotonin
depletion counteracts sex differences in anxiety-related behaviour in rat.
Psychopharmacology 230(1), 29–35.
Näslund J, Studer E, Petterson R, Hagsater M, Nilsson S, Nissbrandt H and
Eriksson E (2015). Differences in anxiety-like behaviour within a batch of
Wistar rats are associated with differences in serotonergic transmission,
enhanced by acute SSRI administration and abolished by serotonin
depletion. International Journal of Neuropsychopharmacology 18(8),
pyv018.
Neumaier JF, Root DC and Hamblin MW (1996). Chronic fluoxetine
reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential
manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 15(5),
515–522.
Nibuya M, Morinobu S and Duman RS (1995). Regulation of BDNF and trkB
mRNA in rat brain by chronic electroconvulsive seizure and antidepressant
drug treatments. Journal of Neuroscience 15(11), 7539–7547.
Pattyn A, Simplicio N, van Doorninck JH, Goridis C, Guillemot F and
Brunet JF (2004). Ascl1/Mash1 is required for the development of central
serotonergic neurons. Nature Neuroscience 7(6), 589–595.
Popova NK and Naumenko VS (2013). 5-HT1A receptor as a key player in the
brain 5-HT system. Reviews in the Neurosciences 24(2), 191–204.
Rattray M, Baldessari S, Gobbi M, Mennini T, Samanin R and Bendotti C
(1996). p-Chlorphenylalanine changes serotonin transporter mRNA
levels and expression of the gene product. Journal of Neurochemistry
67(2), 463–472.
Rumajogee P, Vergé D, Darmon M, Brisorgueil MJ, Hamon M and
Miquel MC (2005). Rapid up-regulation of the neuronal serotoninergic
phenotype by brain-derived neurotrophic factor and cyclic adenosine
monophosphate: relations with raphe astrocytes. Journal of Neuroscience
Research 81(4), 481–487.
Sabol KE, Richards JB and Seiden LS (1992). Fluoxetine attenuates
the DL-fenfluramine-induced increase in extracellular serotonin as
measured by in vivo dialysis. Brain Research 585(1–2), 421–424.
Sarkissian CF, Wurtman RJ, Morse AN and Gleason R (1990). Effects of
fluoxetine or D-fenfluramine on serotonin release from, and levels in, rat
frontal cortex. Brain Research 529(1–2), 294–301.
Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR,
Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson
Sand Beyer CE (2008). Neuropharmacological profile of novel
and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.
Neuropsychopharmacology 33(6), 1323–1335.
ShenHW,Numachi Y, Yoshida S, FujiyamaK, Toda S, Awata S,MatsuokaH
and Sato M (2003). Electroconvulsive shock increases serotonin transporter
in the rat frontal cortex. Neuroscience Letters 341(2), 170–172.
Shishkina GT, Kalinina TS and Dygalo NN (2007). Up-regulation
of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine
treatment correlates with its antidepressant effect. Neuroscience 150(2),
404–412.
Sundblad C and Eriksson E (1997). Reduced extracellular levels of serotonin in
the amygdala of androgenized female rats. European Neuropsychopharmacology
7(4), 253–259.
Tagliamonte A, Tagliamonte P, Gessa GL and Brodie BB (1969). Compulsive
sexual activity induced by p-chlorophenylalanine in normal and pinealec-
tomized male rats. Science 166(3911), 1433–1435.
Torres G, Horowitz JM, Laflamme N and Rivest S (1998). Fluoxetine induces
the transcription of genes encoding c-fos, corticotropin-releasing factor and
its type 1 receptor in rat brain. Neuroscience 87(2), 463–477.
Treit D, Robinson A, Rotzinger S and Pesold C (1993). Anxiolytic effects of
serotonergic interventions in the shock-probe burying test and the elevated
plus-maze test. Behavioural Brain Research 54(1), 23–34.
Vega Matuszcyk J, Larsson K and Eriksson E (1998). The selective serotonin
reuptake inhibitor fluoxetine reduces sexual motivation in male rats.
Pharmacology, Biochemistry and Behavior 60(2), 527–532.
Xiao Q, Pawlyk A and Tejani-Butt SM (1999). Reserpine modulates serotonin
transporter mRNA levels in the rat brain. Life Sciences 64(1), 63–68.
Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno SI and Okada M (2011).
Different actions for acute and chronic administration of mirtazapine on
serotonergic transmission associated with raphe nuclei and their innervation
cortical regions. Neuropharmacology 60(4), 550–560.
Zetterström TS, Pei Q, Madhav TR, Coppell AL, Lewis L and
Grahame-Smith DG (1999). Manipulations of brain 5-HT levels affect




Downloaded from https://www.cambridge.org/core. Chalmers Tekniska Högskola, on 03 Dec 2020 at 13:35:04, subject to the Cambridge Core terms of use, available at
